Form 4: Regeneron Director Arthur F. Ryan Disposes of Shares Under 10b5-1 Plan

Director Arthur F. Ryan sold shares of Regeneron Pharmaceuticals, Inc. (REGN) on August 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On August 1, 2024, Arthur F. Ryan, a director of Regeneron Pharmaceuticals, Inc., disposed of shares of the company's common stock.
• The sales were executed under a pre-arranged trading plan intended to comply with Rule 10b5-1(c), which was adopted on August 7, 2023.
• A total of 77 shares were sold at various prices ranging from $1,053.22 to $1,099.98.
• The transactions resulted in a decrease in Ryan's direct holdings, with the remaining balance totaling 17,783 shares.
• The reporting person will provide full information regarding the number of shares sold at each separate price upon request by the Commission staff, the Company, or a security holder of the Company.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating routine stock sales by a company director under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of trading on inside information. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.

Key Dates